Literature DB >> 31089249

Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia.

Stephan Stilgenbauer1, Thérèse Aurran Schleinitz2, Barbara Eichhorst3, Fabian Lang4, Fritz Offner5, Jean-François Rossi6, Wilfried Schroyens7, Eric Van Den Neste8, Loïc Ysebaert9, Ute von Wangenheim10, Uta Ursula Kress10, Petra Blum10, Thorsten Zenz11,12.   

Abstract

Entities:  

Year:  2019        PMID： 31089249     DOI： 10.1038/s41375-019-0475-z

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  10 in total

1.  Six-packed antibodies punch better.

Authors:  Christoph Rader; Adrian Wiestner
Journal:  Haematologica       Date:  2019-09       Impact factor: 9.941

2.  Overexpression of Tetraspanin31 contributes to malignant potential and poor outcomes in gastric cancer.

Authors:  Yusuke Takashima; Shuhei Komatsu; Takuma Ohashi; Jun Kiuchi; Hajime Kamiya; Hiroki Shimizu; Tomohiro Arita; Hirotaka Konishi; Atsushi Shiozaki; Takeshi Kubota; Kazuma Okamoto; Hitoshi Fujiwara; Hitoshi Tsuda; Eigo Otsuji
Journal:  Cancer Sci       Date:  2022-04-01       Impact factor: 6.518

Review 3.  Tspan18 is a novel regulator of thrombo-inflammation.

Authors:  Rebecca L Gavin; Chek Ziu Koo; Michael G Tomlinson
Journal:  Med Microbiol Immunol       Date:  2020-05-23       Impact factor: 3.402

4.  CD37 high expression as a potential biomarker and association with poor outcome in acute myeloid leukemia.

Authors:  Qi Zhang; Qi Han; Jie Zi; Chunhua Song; Zheng Ge
Journal:  Biosci Rep       Date:  2020-05-29       Impact factor: 3.840

Review 5.  Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia.

Authors:  Valentina Griggio; Francesca Perutelli; Chiara Salvetti; Elia Boccellato; Mario Boccadoro; Candida Vitale; Marta Coscia
Journal:  Front Immunol       Date:  2020-11-18       Impact factor: 7.561

Review 6.  NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications.

Authors:  Paolo Sportoletti; Filomena De Falco; Beatrice Del Papa; Stefano Baldoni; Valerio Guarente; Andrea Marra; Erica Dorillo; Chiara Rompietti; Francesco Maria Adamo; Loredana Ruggeri; Mauro Di Ianni; Emanuela Rosati
Journal:  Int J Mol Sci       Date:  2021-06-22       Impact factor: 5.923

7.  A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

Authors:  Alexey V Danilov; Stephen E Spurgeon; Tanya Siddiqi; Anne-Marie Quinson; Daniela Maier; Dionne Smith; Jennifer R Brown
Journal:  Invest New Drugs       Date:  2021-03-08       Impact factor: 3.850

8.  A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma.

Authors:  Monica Balzarotti; Massimo Magagnoli; Miguel Ángel Canales; Paolo Corradini; Carlos Grande; Juan-Manuel Sancho; Francesco Zaja; Anne-Marie Quinson; Valérie Belsack; Daniela Maier; Carmelo Carlo-Stella
Journal:  Invest New Drugs       Date:  2021-02-01       Impact factor: 3.850

9.  Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

Authors:  Frank Kroschinsky; Jan Moritz Middeke; Martin Janz; Georg Lenz; Mathias Witzens-Harig; Reda Bouabdallah; Paul La Rosée; Andreas Viardot; Gilles Salles; Seok Jin Kim; Tae Min Kim; Oliver Ottmann; Joerg Chromik; Anne-Marie Quinson; Ute von Wangenheim; Ute Burkard; Andreas Berk; Norbert Schmitz
Journal:  Invest New Drugs       Date:  2020-03-14       Impact factor: 3.850

Review 10.  Tetraspanins as Potential Modulators of Glutamatergic Synaptic Function.

Authors:  Amina Becic; Jennifer Leifeld; Javeria Shaukat; Michael Hollmann
Journal:  Front Mol Neurosci       Date:  2022-01-03       Impact factor: 5.639
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.